SuperworthCoherus Oncology EPS CHRS
Diluted earnings per share by quarter and over the last twelve months, from 2013.
- Last 12 months, to Jun 30, 2026
- −$1.03
- Latest quarter, Q2 FY26
- −$0.13
- −105% on a year earlier
- Fiscal year 2025
- $1.46
- +441% on the year before
Coherus Oncology's earnings per share was −$1.03 over the twelve months to Jun 30, 2026, down 166% on a year earlier.
In its latest quarter, Q2 FY26, it was −$0.13, down 105% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | $1.46 | +441% |
| FY2024 | $0.27 | n/a |
| FY2023 | −$2.57 | n/a |
| FY2022 | −$3.76 | n/a |
| FY2021 | −$3.86 | −338% |
| FY2020 | $1.62 | +36% |
| FY2019 | $1.19 | n/a |
| FY2018 | −$3.21 | n/a |
| FY2017 | −$4.55 | n/a |
| FY2016 | −$3.43 | n/a |
| FY2015 | −$5.99 | n/a |
| FY2014 | −$15.25 | n/a |
| FY2013 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | −$0.13 | −105% | −$1.03 | |
| Q1 FY26 | −$0.28 | n/a | $1.67 | |
| Q4 FY25 | −$0.31 | n/a | $1.46 | |
| Q3 FY25 | −$0.31 | n/a | $1.33 | |
| Q2 FY25 | $2.57 | n/a | $1.55 | |
| Q1 FY25 | −$0.49 | −154% | −$1.13 | |
| Q4 FY24 | −$0.44 | n/a | $0.27 | |
| Q3 FY24 | −$0.09 | n/a | $0.00 | |
| Q2 FY24 | −$0.11 | n/a | −$0.32 | |
| Q1 FY24 | $0.91 | n/a | −$0.70 | |
| Q4 FY23 | −$0.71 | n/a | −$2.57 | |
| Q3 FY23 | −$0.41 | n/a | −$2.62 |
Against its peers
Companies in Healthcare nearest Coherus Oncology's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| CHRSCoherus Oncology | −$1.03 | −166% a year |
| PDEXPro DEX | $4.11 | +52% a year |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| NATRNatures Sunshine Products | $1.01 | +36% a year |
| ELMDElectromed | $1.31 | +56% a year |
| UTMDUtah Medical Products | $3.28 | −12% a year |
| KEQUKewaunee Scientific | $2.76 | −33% a year |
| ICCCImmucell | $0.08 | −58% a year |
| INFUInfuSystem | $0.41 | +78% a year |
| LFVNLifevantage | $0.40 | −46% a year |
| VMDViemed Healthcare | $0.36 | +6% a year |
| Peer median | $0.71 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Coherus Oncology
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.